(20R)-Ginsenoside Rg3
Based on 5 publication(s) in Google Scholar
(20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits angiogenesis, and has anti-carcinogenic and antimetastatic effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.84%
- CAS. Nr.: 38243-03-7
- Formel: C42H72O13
- Molecular Weight:785.01
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (20R)-Ginsenoside Rg3
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
Flow Cytometry
-
WB
-
IHC
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
55.36 μg/mL
Compound: 20S-Rg3
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24321343] |
| HepG2 | IC50 |
54 μg/mL
Compound: Rg3
|
Cytotoxicity against human HepG2 cells after 24 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells after 24 hrs by CCK-8 assay
|
[PMID: 25227718] |
(20R)-ginsenoside Rg3 inhibits the proliferation of human umbilical vein endothelial cells (HUVEC) with an IC50 of 10 nM[1].
(20R)-ginsenoside Rg3 also dose dependently suppresses the capillary tube formation of HUVEC on the Matrigel in the presence or absence of 20 ng/mL VEGF[1].
(20R)-ginsenoside Rg3 significantly attenuates the VEGF-induced chemoinvasion of HUVEC and ex vivo microvascular sprouting in rat aortic ring assay[1].
(20R)-ginsenoside Rg3 (150 and 600 nM) remarkably abolishes the basic fibroblast growth factor (bFGF)-induced angiogenesis in an in vivo Matrigel plug assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVEC
-
Concentration:1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:48 h
-
Result:Inhibited the proliferation of HUVEC.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Kunming mice weighing 18-22 g[2]
-
Dosage:0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg (5 μL each nostril)
-
Administration:Intranasal administration; for 2 weeks
-
Result:Significantly prolonged the weight-loaded swimming time, and also increased the hepatic glycogen levels.
Chemical Information
-
CAS. Nr. 38243-03-7
-
Appearance Solid
-
Molecular Weight 785.01
-
Formel C42H72O13
-
Color White to off-white
-
SMILES
O[C@@H]([C@@H]([C@@H](CO)O1)O)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)[C@@H]1O[C@H]3CC[C@]4(C)[C@@]5([H])C[C@@H](O)[C@]6([H])[C@@H]([C@](C)(O)CC/C=C(C)\C)CC[C@](C)6[C@@](C)5CCC4C3(C)C
-
Synonyms
(20R)-Propanaxadiol; R-ginsenoside Rg3
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Ginsenoside Rg3 Restores Mitochondrial Cardiolipin Homeostasis via GRB2 to Prevent Parkinson's Disease. [Abstract]2024 Oct;11(39):e2403058. PMID: 39159293 -
Phytomedicine
Rg3 inhibits hypoxia-induced tumor exosomes from boosting pancreatic cancer vasculogenic mimicry through the HIF-1α/LARS1/mTOR axis. [Abstract]2025 Apr:139:156437. PMID: 39955826 -
Phytomedicine
Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma. [Abstract]2024 Apr:126:155402. PMID: 38350242 -
Phytother Res
20(R)-Ginsenoside Rg3 Suppresses P-Glycoprotein-Mediated Multidrug Resistance in A549/Taxol Cells by Targeting MDM2-IκB-α Signaling Axis. [Abstract]2026 Apr;40(4):1935-1950. PMID: 41630373
(20R)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1935-1950. [Abstract]
Cells were treated with (20R)-Ginsenoside Rg3 (Rg3), taxol (4nM for A549 cells, 500nM for A549/Taxol cells) or combination for 48h before MTT assay.
(20R)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1935-1950. [Abstract]
A549/Taxol cells were incubated with FITC-Taxol or combination with (20R)-Ginsenoside Rg3 (Rg3) (4μM) or VRP for 48h, then observed under confocal microscope.
(20R)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1935-1950. [Abstract]
A549/Taxol cells were incubated with FITC-Taxol or combination with (20R)-Ginsenoside Rg3 (Rg3) (4μM) or VRP for 48h, then detected using flow cytometry.
(20R)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1935-1950. [Abstract]
Western blot results of MDM2, NF-κB, p-NF-κB and IκB-α in total and NF-κB in nucleus and cytoplasm after treatment with taxol (500nM), (20R)-Ginsenoside Rg3 (Rg3) (4μM) or in combination with Flag-MDM2 plasmid for 48h.
(20R)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1935-1950. [Abstract]
Immunohistochemical staining of MDM2, P-gp, p-NF-κB and IκB-α in tumor tissues treated with (20R)-Ginsenoside Rg3 (Rg3) (8 mg/kg, i.g.).
-
Oxid Med Cell Longev
Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation. [Abstract]2021 Oct 7;2021:3520034. PMID: 34659631
Lösungsmittel & Löslichkeit
DMSO : 25 mg/mL (31.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Yue PY, et al. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol. 2006 Aug 14;72(4):437-45. [Content Brief]
[2]. Wenyan Tang, et al. The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration. Biol Pharm Bull. 2008 Nov;31(11):2024-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL | 31.8467 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | 6.3693 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL | 3.1847 mL | |
| 15 mM | 0.0849 mL | 0.4246 mL | 0.8492 mL | 2.1231 mL | |
| 20 mM | 0.0637 mL | 0.3185 mL | 0.6369 mL | 1.5923 mL | |
| 25 mM | 0.0510 mL | 0.2548 mL | 0.5095 mL | 1.2739 mL | |
| 30 mM | 0.0425 mL | 0.2123 mL | 0.4246 mL | 1.0616 mL |
(20R)-Ginsenoside Rg3 Related Classifications
HY-N1376 Related Classifications
Powered by Bioz